Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients

Table 2 Treatment at time of the first assessment of the 60 patients identified

Treatment	Previously	At start of anti-TNF	After 12 months on anti-TNF
MTX/AZA/HQL¹	48 (98%), n = 49	43 (80%), n = 56	41 (89%), n = 46
Cyclophosphamide	26 (43%), n = 60	3 (5%), n = 60	0, n = 43
Immunoglobulin	5 (11%), n = 47	6 (13%), n = 46	1 (2.5%), n = 40
Oral steroids	47 (92%), n = 51	26 (68%), n = 38	26 (58%), n = 45
2 or more DMARDs	48 (98%), n = 49	30 (64%), n = 47

MTX methotrexate, AZA azathioprine, HQL hydroxychloroquine, n (%) absolute numbers (percentages) from the number of patients with available data
¹Mycophenylate mofetil (MMF) was not used in the patients in this study

ISSN: 1478-6362